effective October 1, 1987 to those organizations and individuals not directly involved with implementation of the National Flood Insurance Program. Under this proposal, all entities *except* Federal, State and local governments, lending institutions, insurance agents, insurance brokers, and Writer Your Own companies, would be charged for maps.

The proposed fee is $5.00 per order up to 10 map panels and $.60 for each additional map panel. This fee schedule includes the postage cost. A one panel community map would cost a total of $5.00 whereas a community whose map consists of 100 panels would cost $59.00. The average map order is currently 14 panels and would cost $7.40.

Fee payments will be required in advance of the shipments. The proposed payment mechanisms are as follows: establishment of a cash account, or prepayment for an individual order by check or money order, or use a Visa or Master Card credit card.

Anyone who has an interest in the fee charge system should provide their comments in accordance with the date and address listed above.

Harold T. Duryee,

Administrator, Federal Insurance Administration.

[FR Doc. 87-4088 Filed 3-2-87; 8:45 am]

BILLING CODE 6718-03-M

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License Revocations; Associated Forwarders, Inc. et al.

Notice is hereby given that the following ocean freight forwarder licenses have been revoked by the Federal Maritime Commission pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. app. 1718) and the regulations of the Commission pertaining to the licensing of ocean freight forwarders, 46 CFR Part 510.

License No.: 2376
Name: Associated Forwarders, Inc.
Address: 1000 ITM Bldg., New Orleans, LA 70130
Date Revoked: December 30, 1986
Reason: Requested revocation voluntarily

License No.: 2589
Name: Accelerated Customs Brokers, Inc.
Address: 9310 Bellanca Avenue, Los Angeles, CA 90045
Date Revoked: January 20, 1987
Reason: Surrendered license voluntarily

License No.: 1920
Name: IFC Corporation and IFC Corporation dba International IFC Corporation
Address: 12333 S. Latrobe, Chicago, IL 609658
Date Revoked: January 28, 1987
Reason: Failed to maintain a valid surety bond

License No.: 2772
Name: Paralia, Inc. dba Paralia Corporation
Address: 80 Broad Street, Boston, MA 02110
Date Revoked: February 4, 1987
Reason: Failed to maintain a valid surety bond

License No.: 1215
Name: Ingham International, Inc.
Address: 7550 24th Ave. So., #166, Minneapolis, MN 55450
Date Revoked: February 5, 1987
Reason: Failed to maintain a valid surety bond

License No.: 2799
Name: Denver Moving & Storage, Inc., DMS International Division
Address: 2133 South Wabash St., Denver, CO 80231
Date Revoked: February 7, 1987
Reason: Failed to maintain a valid surety bond

License No.: 1522
Name: Inter-Hemisphere Service Co., Inc.
Address: 482 Manor Rd., Staten Island, NY 10314
Date Revoked: February 10, 1987
Reason: Failed to maintain a valid surety bond

License No.: 1191
Name: Tuya International Corporation
Address: 1351 N.W. 78th Avenue, Miami, FL 33126
Date Revoked: February 17, 1987
Reason: Requested revocation voluntarily.

Robert G. Drew,

Director, Bureau of Domestic Regulation.

[FR Doc. 87-4360 Filed 3-2-87; 8:45 am]

BILLING CODE 6730-01-M

[Docket No. 87-2]

Investigation of Rebates and Other Malpractices; Yangming Marine Line, a.k.a. Yangming Marine Transport Corporation and Yang Ming Line; Order

This proceeding is instituted pursuant to sections 10, 11 and 13 of the Shipping Act of 1984, 46 U.S.C. app. 1709, 1710 and 1712, and sections 16, 18, 22 and 32 of the Shipping Act, 1916, 46 U.S.C. app. 815, 817, 821 and 831.

Yangming Marine Line (also known as Yangming Marine Transport Corporation and Yang Ming Line, hereafter YML) is an ocean common carrier domiciled in Taiwan which operates in the trades between the Far East and the United States.

It appears that during the period since January 1, 1983, YML may have paid rebates to certain Taiwanese consignees and committed other malpractices in connection with shipments of cotton from the United States. It further appears that during this period YML may have participated in an arrangement with others to pay expenses incurred by certain YML shippers or consignees of commodities other than cotton (e.g., beet pulp pellets, meat and bone meal, and corn gluten meal). This arrangement also may have been used to camouflage payments for malpractices committed by YML.

Accordingly, it appears that during the period since January 1, 1983, YML may have violated sections 10(b) (1)–(4), (6) (A), (8), (10) and (11) of the Shipping Act of 1984 and sections 16 First and Second and 18(b)(3) of the Shipping Act, 1916.

Now therefore it is ordered, That pursuant to sections 10, 11 and 13 of the Shipping Act of 1984 and sections 16, 18, 22 and 32 of the Shipping Act, 1916, an investigation into the activities of YML in the **Federal Register**/Taiwan trade during the period since January 1, 1983, is instituted to determine the following:

1. Whether YML violated sections 10(b)(1)–(4), (6) (A), (8), (10) and (11) of the Shipping Act of 1984 and sections 16 First and Second and 18(b)(3) of the Shipping Act, 1916, by charging, demanding, collecting or receiving different compensation for the transportation of property and for services rendered in connection therewith than the rates and charges shown in its tariffs and service contracts; rebating, refunding or remitting a portion of its rates in a manner not in accordance with its tariffs and service contracts; extending privileges, concessions, equipment or facilities in a manner not in accordance with its tariffs or service contracts; allowing persons to obtain transportation for property at less than the rates and charges established in its tariffs or service contracts by unjust and unfair devices and means; engaging in unfair or unjustly discriminatory practices in the matter of rates; offering or paying deferred rebates; demanding, charging or collecting rates and charges that were unjustly discriminatory between shippers; and by giving unreasonable preferences and advantages to any particular person or description of traffic.

2. In the event YML is found to have violated any of the above-cited provisions, whether civil penalties should be assessed, and, if so, the amount of such penalties; and

3. What other remedial action should be taken, including but not limited to cease and desist orders and suspension and cancellation of tariffs.

It is further ordered, That a public hearing be held in this proceeding and that the matter be assigned for hearing before an Administrative Law Judge, of the Commission's Office of Administrative Law Judges, at a date and place to be hereafter determined by the Administrative Law Judge, in compliance with Rule 61 of the Commission's Rules of Practice and Procedure, 46 CFR 502.61;

It is further ordered, That YML is designated Respondent in this proceeding;

It is further ordered, That the Commission's Bureau of Hearing Counsel is designated a party to this proceeding;

It is further ordered, That notice of this Order be published in the **Federal Register**, and a copy be served on parties designated herein;

It is further ordered, That other persons having an interest in participating in this proceeding may file petitions for leave to intervene in accordance with Rule 72 of the Commission's Rules of Practice and Procedure, 46 CFR 502.72;

It is further ordered, That all future notices, orders, and decisions issued in this proceeding, including notice of the time and place of hearing or prehearing conference, shall be served on parties of record.

It is further ordered, That all documents submitted by any party of record in this proceeding shall be directed to the Secretary, Federal Maritime Commission, Washington, DC 20573, in accordance with Rule 118 of the Commission's Rules of Practice and Procedure, 46 CFR 502.118, and shall be served on parties of record;

It is further ordered, That in accordance with Rule 61 of the Commission's Rules of Practice and Procedure, the initial decision of the presiding officer in this proceeding shall be issued by May 25, 1988, and the final decision of the Commission shall be issued by September 26, 1988.

By the Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 87-4359 Filed 3-2-87; 8:45 am]

BILLING CODE 6730-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 87F-0003]

E.I. du Pont de Nemours and Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that E.I. du Pont de Nemours & Co., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a polymer manufactured by the condensation of hexamethylenediamine, terephthalic acid and isophthalic acd for food-contact applications.

FOR FURTHER INFORMATION CONTACT: Edward J. Machuga, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 7B3982) has been filed by E.I. du Pont de Nemours & Co,, Wilmington, DE 19898, proposing that § 177.1500 *Nylon resins* (21 CFR 177.1500) be amended to provide for the safe use of a polymer manufactured by the condensation of hexamethylenediamine, terephthalic acid and isophthalic acid for food-contact applications.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated February 9, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87-4346 Filed 3-2-87; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 86F-0507]

Radiation Technology, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Radiation Technology, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a source of gamma radiation to irradiate poultry for the purpose of extending shelf-life and reducing the risk of salmonella poisoning.

FOR FURTHER INFORMATION CONTACT: Clyde A. Takeguchi, Center for Food Safety and Applied Nutrition (HFF-330), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202-472-5740.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 8M3422) has been filed by Radiation Technology, Inc., 108 Lake Denmark Rd., Rockaway, NJ 07866, proposing that § 179.26 *Ionizing radiation for the treatment of food* (21 CFR 179.26) be amended to provide for the safe use of a source of gamma radiation to irradiate poultry for the purpose of extending shelf-life and reducing the risk of salmonella poisoning.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: February 9, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87-4347 Filed 3-2-87; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 87M-0027]

Beiersdorf Inc.; Premarket Approval of Implast® Bone Cement

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Beiersdorf, Inc., Norwalk, CT, for premarket approval, under the Medical Device Amendments of 1976, of the Implast® Bone Cement. After reviewing the recommendation of the Orthopedic and Rehabilitation Devices Panel, FDA's Center for Devices and Radiological

Health (CDRH) notified the applicant of the approval of the application.

DATE: Petitions for administrative review by April 2, 1987.

ADDRESS: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Thomas J. Callahan, Center for Devices and Radiological Health (HFZ–410), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–7156.

SUPPLEMENTARY INFORMATION: On April 23, 1986, Beiersdorf, Inc., Norwalk, CT 06856–5529, submitted to CDRH an application for premarket approval of the Implast® Bone Cement. Implast Bone Cement is indicated for use in arthroplastic procedures of the hip, knee, and other joints, for the fixation of plastic and metal prostheses to living bone in orthopedic musculoskeletal surgical procedures for osteoarthritis, rheumatoid arthritis, traumatic arthritis, avascular necrosis, nonunion of fractures of the neck of the femur, sickle cell anemia, collagen disease, osteoporosis, severe joint destruction secondary to trauma, or other conditions, to fix unstable fractures in individuals with metastatic malignancies, and revisions of previous arthroplasty procedures.

On October 31, 1986, the Orthopedic and Rehabilitation Devices Panel, an FDA advisory committee, reviewed and recommended approval of the application. On January 16, 1987, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

A copy of all approved labeling is available for public inspection at CDRH—contact Thomas J. Callahan (HFZ–410), address above.

Opportunity for Administrative Review

Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360(g)), for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before April 2, 1987, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h), 90 Stat. 554–555, 571 (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: February 20, 1987.

John C. Villforth,

Director, Center for Devices and Radiological Health.

[FR Doc. 87–4345 Filed 3–2–87; 8:45 am]

BILLING CODE 4160–01–M

National Institutes of Health

National Institutue on Aging; Notice of Meetings

Pursuant to Pub. L. 92–463, notice is hereby given of meetings of the National Institute on Aging.

These meetings will be open to the public to discuss administrative details for approximately one-half hour at the beginning of the first session of the first day of the meetings. Attendance by the public will be limited to space available.

These meetings will be closed to the public as indicated below in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92–463, for the review, discussion, and evaluation of individual research grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. June C. McCann, Committee Management Officer, National Institute on Aging, Building 31, Room 5C05, National Institutes of Health, Bethesda, Maryland, 20892, (301/496–9322), will provide summaries of the meetings and rosters of the committee members upon request. Other information pertaining to the meetings can be obtained from the Executive Secretary indicated.

Name of Committee: Geriatrics Review Committee

Executive Secretary: Dr. Marvin Kalt, Building 31, Room 5C12, National Institutes of Health, Bethesda, Maryland 20892, Phone: 301/496–9666

Dates of Meeting: March 11–12, 1987

Place of Meeting: National Institutes of Health, Building 31C, Conference Room 7, 9000 Rockville Pike, Bethesda, Maryland 20892

Open: March 11, 8:30 a.m. to 9:00 a.m.

Closed: March 11, 9:00 a.m. to recess, March 12, 8:30 a.m. to adjournment

Name of Committee: Aging Review Committee A

Executive Secretary: Dr. Walter Spieth, Building 31, Room 5C12, National Institutes of Health, Bethesda, Maryland, 20892, Phone: 301/496–9666

Date of Meeting: March 18–19, 1987

Place of Meeting: National Institutes of Health, Building 31C, Conference Room 7, 9000 Rockville Pike, Bethesda, Maryland 20892

Open: March 18, 8:30 a.m. to 9:00 a.m.

Closed: March 18, 9:00 a.m. to recess, March 19, 8:30 a.m. to adjournment

Name of Committee: Aging Review Committee B

Executive Secretary: Dr. Marvin Kalt, Building 31, Room 5C12, National Institutes of Health, Bethesda, Maryland 20892, Phone: 301/496–9666

Dates of Meeting: National Institutes of Health, Building 31C, Conference Room 8, 9000 Rockville Pike, Bethesda, Maryland 20892

Open: March 19, 8:30 a.m. to 9:00 a.m.

Closed: March 19, 8:30 a.m. to recess, March 20, 8:30 a.m. to adjournment